In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Oxytocin is normally administered following delivery in pregnant patients to reduce
postpartum bleeding by increasing uterine tone. It is unclear whether the use of intravenous
oxytocin alters coagulation in pregnant patients. The purpose of the in-vitro study is to
assess the coagulation changes of oxytocin in blood samples from pregnant patients using
thromboelastrography (TEG). TEG is a point-of-care device which measures the viscoelastic
properties of clot formation, and can provide rapid and detailed information about
coagulation changes. We aim to collect blood samples from pregnant patients to assess the
in-vitro effects of synthetic oxytocin on coagulation using TEG.